Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab)
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
TARRYTOWN, N.Y., July 1, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that it has completed the acquisition of Sanofi's stake in Libtayo® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
In 2015, Regeneron and Sanofi entered into the Immuno-oncology License and Collaboration Agreement whereby the companies split Libtayo's world
